| Project/Area Number |
10670978
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Hematology
|
|---|
| Research Institution | Saitama Cancer Center |
|---|
Principal Investigator |
OKABE-KADO Junko SAITAMA CANCER CENTER, RESEARCH INSTITUTE, CHIEF RESEARCHER, 研究所, 主任研究員 (30161136)
|
|---|
| Project Period (FY) |
1998 – 2000
|
| Project Status |
Completed (Fiscal Year 2000)
|
| Budget Amount *help |
¥3,200,000 (Direct Cost: ¥3,200,000)
Fiscal Year 2000: ¥1,000,000 (Direct Cost: ¥1,000,000)
Fiscal Year 1999: ¥1,100,000 (Direct Cost: ¥1,100,000)
Fiscal Year 1998: ¥1,100,000 (Direct Cost: ¥1,100,000)
|
|---|
| Keywords | NM23 / PROGNOSTIC FACTOR / AML / LYMPHOMA / ELISA / SERUM / ELISA法 / 文化誘導抑制因子 / 白血病予後因子 |
|---|
| Research Abstract |
Expression levels of nm23-H1 and nm23-H2 mRNA in acute myeloid leukemia (AML) samples were significantly higher than that in normal blood cells, and a higher level of nm23-H1 expression was correlated with a poor prognosis in AML.To apply the prognosis based on the overexpression for other tumors, we made a detection system, sandwich ELISA for serum NM23-H1 protein. Using this system, we measured many hematological malignacies and malignant lymphoma. We showed the levels of serum NM23-H1 proteins of various hematological malignancies and the important function of serum NM23-H1 protein as a prognostic factor for AML and malignant lymphoma, especially aggressive non-Hodgkin's lymphoma.
|
